Abstract
The European regulation introduced in 2007 a new class of biological products, named “Advanced Therapy Medicinal Products” (ATMPs) in order to clarify and harmonize the authorization rules of these products in Europe as well as to facilitate their availability for the patients. ATMPs include somatic cell therapy and gene therapy medicinal products, products derived from cellular and tissue engineering, possibly combined with medical devices. The classification of tissue or cell-based therapeutic approaches as medicinal products introduces specific legislation concerning their development and clinical trials, manufacture and marketing authorization. Most of the ATMPs come from the progress made in recent years in biotechnology and also in the knowledge of stem cell biology. The clinical applications are numerous, mainly in hematology and oncology, but also in the field of regenerative medicine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
